RNA sequencing of skin samples from healthy volunteers and from HS and AD patients treated with KT-474

Skin biopsies were collected from healthy volunteers and from lesions of atopic dermatitis (AD) and hidradenitis suppurativa (HS) patients pre-treatment and after 28 days of treatment with KT-474, a selective IRAK4 degrader. This data was collected as part of a Phase 1 trial to assess safety, pharmacokinetics, pharmacodynamics, and clinical activity (ClinicalTrials.gov: NCT04772885).

皮肤活检样本采集自健康志愿者，以及特应性皮炎（atopic dermatitis, AD）和化脓性汗腺炎（hidradenitis suppurativa, HS）患者的皮损部位，采样时点涵盖治疗前以及接受选择性IRAK4降解剂KT-474治疗28天后。本数据集为一项评估安全性、药代动力学、药效学及临床活性的I期临床试验的组成部分（ClinicalTrials.gov编号：NCT04772885）。